Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

UPDATE: Heron Therapeutics Q3 Adj. EPS $(0.04) Misses $(0.01) Estimate, Sales $38.213M Miss $39.031M Estimate

Author: Benzinga Newsdesk | November 04, 2025 09:37am
Heron Therapeutics (NASDAQ:HRTX) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.01) by 166.67 percent. This is a 33.33 percent decrease over losses of $(0.03) per share from the same period last year. The company reported quarterly sales of $38.213 million which missed the analyst consensus estimate of $39.031 million by 2.10 percent. This is a 16.47 percent increase over sales of $32.810 million the same period last year.

Posted In: HRTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist